BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St edges lower as chips fall; markets assess big bank earnings
- Oil prices mixed as US-Russia diesel deal hopes offset Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.12 -2.29%
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PGR, OMID, ACI, More
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Citigroup beats Q3 estimates as revenue hits decade high
- Wells Fargo beats profit estimates despite revenue miss
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
